News & Presentations Filter by Category All 57 Company News 20 Media 13 Newsletter 7 Presentations & Webinars 18 Company News, All Michelle Long 18/11/24 Company News, All Michelle Long 18/11/24 AGM 2024 presentation and results Read More Company News, All Michelle Long 28/10/24 Company News, All Michelle Long 28/10/24 Arovella receives R&D tax rebate of $3.0 million with a further $0.3 million expected Read More Company News, All Michelle Long 14/10/24 Company News, All Michelle Long 14/10/24 Clinical Advisory Board established Read More Company News, All Michelle Long 16/9/24 Company News, All Michelle Long 16/9/24 GO LIME! For Lymphoma this September Read More Company News, All Michelle Long 3/9/24 Company News, All Michelle Long 3/9/24 Arovella added to the MSCI Global Micro Cap Index Read More Company News, All Michelle Long 7/8/24 Company News, All Michelle Long 7/8/24 Positive pre-IND feedback from FDA for ALA-101 Read More Company News, All Michelle Long 5/6/24 Company News, All Michelle Long 5/6/24 Arovella completes manufacturing scale-up Read More Company News, All Michelle Long 23/5/24 Company News, All Michelle Long 23/5/24 EGM presentation and results Read More Company News, All Bradley Cocks 18/4/24 Company News, All Bradley Cocks 18/4/24 Jumar Bioincubator opening, Melbourne | Home to Arovella's new office Read More Company News, All Michelle Long 9/4/24 Company News, All Michelle Long 9/4/24 Arovella presents ALA-101 data at AACR Read More All, Company News Michelle Long 3/4/24 All, Company News Michelle Long 3/4/24 Arovella expands Scientific Advisory Board with the appointment of Professor Gianpietro Dotti Read More Company News, All Bradley Cocks 27/3/24 Company News, All Bradley Cocks 27/3/24 Arovella to present at AACR Annual Meeting Read More Company News, All Bradley Cocks 26/3/24 Company News, All Bradley Cocks 26/3/24 Arovella funded to Phase 1 data: completes $12.5m placement Read More Company News, Presentations & Webinars, All Michelle Long 30/1/24 Company News, Presentations & Webinars, All Michelle Long 30/1/24 Arovella enhances solid tumour pipeline by licensing novel CAR-iNKT cell armouring technology Read More Company News, All Michelle Long 2/1/24 Company News, All Michelle Long 2/1/24 Arovella completes key manufacturing step to progress ALA‐101 to clinic Read More Company News, All Michelle Long 20/11/23 Company News, All Michelle Long 20/11/23 Arovella receives R&D tax credit of $1.94m Read More Company News, All Michelle Long 10/11/23 Company News, All Michelle Long 10/11/23 AGM Chairman's Address and CEO & MD Presentation Read More Company News, All Michelle Long 12/10/23 Company News, All Michelle Long 12/10/23 Arovella licenses novel solid tumour targeting technology Read More Company News, All Michelle Long 11/7/23 Company News, All Michelle Long 11/7/23 Completion of oversubscribed Share Purchase Plan (SPP) Read More Company News, All Michelle Long 11/7/23 Company News, All Michelle Long 11/7/23 Arovella completes $4m placement & launches $1m SPP Read More
Company News, All Michelle Long 18/11/24 Company News, All Michelle Long 18/11/24 AGM 2024 presentation and results Read More
Company News, All Michelle Long 28/10/24 Company News, All Michelle Long 28/10/24 Arovella receives R&D tax rebate of $3.0 million with a further $0.3 million expected Read More
Company News, All Michelle Long 14/10/24 Company News, All Michelle Long 14/10/24 Clinical Advisory Board established Read More
Company News, All Michelle Long 16/9/24 Company News, All Michelle Long 16/9/24 GO LIME! For Lymphoma this September Read More
Company News, All Michelle Long 3/9/24 Company News, All Michelle Long 3/9/24 Arovella added to the MSCI Global Micro Cap Index Read More
Company News, All Michelle Long 7/8/24 Company News, All Michelle Long 7/8/24 Positive pre-IND feedback from FDA for ALA-101 Read More
Company News, All Michelle Long 5/6/24 Company News, All Michelle Long 5/6/24 Arovella completes manufacturing scale-up Read More
Company News, All Michelle Long 23/5/24 Company News, All Michelle Long 23/5/24 EGM presentation and results Read More
Company News, All Bradley Cocks 18/4/24 Company News, All Bradley Cocks 18/4/24 Jumar Bioincubator opening, Melbourne | Home to Arovella's new office Read More
Company News, All Michelle Long 9/4/24 Company News, All Michelle Long 9/4/24 Arovella presents ALA-101 data at AACR Read More
All, Company News Michelle Long 3/4/24 All, Company News Michelle Long 3/4/24 Arovella expands Scientific Advisory Board with the appointment of Professor Gianpietro Dotti Read More
Company News, All Bradley Cocks 27/3/24 Company News, All Bradley Cocks 27/3/24 Arovella to present at AACR Annual Meeting Read More
Company News, All Bradley Cocks 26/3/24 Company News, All Bradley Cocks 26/3/24 Arovella funded to Phase 1 data: completes $12.5m placement Read More
Company News, Presentations & Webinars, All Michelle Long 30/1/24 Company News, Presentations & Webinars, All Michelle Long 30/1/24 Arovella enhances solid tumour pipeline by licensing novel CAR-iNKT cell armouring technology Read More
Company News, All Michelle Long 2/1/24 Company News, All Michelle Long 2/1/24 Arovella completes key manufacturing step to progress ALA‐101 to clinic Read More
Company News, All Michelle Long 20/11/23 Company News, All Michelle Long 20/11/23 Arovella receives R&D tax credit of $1.94m Read More
Company News, All Michelle Long 10/11/23 Company News, All Michelle Long 10/11/23 AGM Chairman's Address and CEO & MD Presentation Read More
Company News, All Michelle Long 12/10/23 Company News, All Michelle Long 12/10/23 Arovella licenses novel solid tumour targeting technology Read More
Company News, All Michelle Long 11/7/23 Company News, All Michelle Long 11/7/23 Completion of oversubscribed Share Purchase Plan (SPP) Read More
Company News, All Michelle Long 11/7/23 Company News, All Michelle Long 11/7/23 Arovella completes $4m placement & launches $1m SPP Read More
